tradingkey.logo

BioXcel Therapeutics To Announce Topline Results From Serenity At-Home Pivotal Phase 3 Safety Trial For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia On August 27, 2025

ReutersAug 26, 2025 8:01 PM

- BioXcel Therapeutics Inc BTAI.O:

  • BIOXCEL THERAPEUTICS TO ANNOUNCE TOPLINE RESULTS FROM SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA ON AUGUST 27, 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI